Xiaosheng Hu

Dr. Xiaosheng Hu

Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2019 in Clinical Science
Verified
Journal Article
Closed access
PDF file
KYKun Yang
Kun Yang
JSJiaran Shi
Jiaran Shi
ZHZhujun Hu
Zhujun Hu
XHXiaosheng Hu
Xiaosheng Hu
Cardiac fibrosis is a common pathological feature of many cardiovascular diseases. The regulatory mechanisms of miRNAs in cardiac fibrosis are still unknown. Previous studies on miR-214-3p in cardiac fibroblasts reached contradictory conclusions. Thus the role of miR-214-3p in cardiac fibrosis deserves further exploration. Using a combination of in vitro and in vivo studies, we identified miR-214-3p as an important regulator of cardiac fibrosis, and the proliferation and activation of cardiac fibroblasts. We demonstrated that the expression of miR-214-3p is down-regulated in TGF-β1-treated myofibroblasts and transverse aortic constriction (TAC)-induced murine model. Additionally, miR-214-3pflox/flox/FSP1-cre mice and miR-214-3pwt/wt/FSP1-cre mice were subjected to TAC operation or sham operation, and the conditional knockout of miR-214-3p in cardiac fibroblasts aggravates TAC-induced cardiac fibrosis. In vitro, our results indicate that miR-214-3p is an important repressor for fibroblasts proliferation and fibroblast-to-myofibroblast transition by functionally targeting NOD-like receptor family CARD domain containing 5 (NLRC5). In conclusion, our findings show that the deficiency of miR-214-3p exacerbates cardiac fibrosis and reveal a novel miR-214-3p/NLRC5 axis in the regulation of cardiac fibrosis.

14 September 2020 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
JSJiaran Shi
Jiaran Shi
LCLeiyang Chen
Leiyang Chen
SCShi Chen
Shi Chen
BWBifeng Wu
Bifeng Wu
KYKun Yang
Kun Yang
XHXiaosheng Hu
Xiaosheng Hu
Background: Circulating long noncoding RNA (lncRNA) plays a vital role in clinical disease diagnosis and prognosis. Here, we evaluate the role of a lncRNA, named growth arrest specific 5 (GAS5), in atrial fibrillation (AF).Methods: Expression of GAS5 was measured by qRT‐PCR. Diagnostic and prognostic values of GAS5 were assessed by the receiver operating characteristics curve (ROC), Kaplan–Meier (KM) and Cox regression analyses.Results: A total of 173 participants were enrolled in this study. Circulating GAS5 expression was significantly down‐regulated in AF patients. This change occurred prior to enlargement of the left atrial volume and was strongly associated with AF progression, which demonstrates the potential use of GAS5 as an early biomarker. The area under the ROC curve (AUC) was 0.858 (95% CI 0.789‐0.926,P < .001). Seventy of the 85 AF patients received radiofrequency catheter ablation (RFCA), and 22 (31.4%) had relapsed by the 1‐year follow‐up. The KM analysis (log‐rank test,P = .031) and multivariable Cox analysis (HR = 0.127, 95% CI 0.026‐0.616;P = .01) revealed that GAS5 has a role in predicting recurrence after RFCA.Conclusion: Circulating lncRNA GAS5 is a potential biomarker for AF diagnosis and prognosis. Down‐regulation of GAS5 occurs prior to left atrial enlargement and can be used for the prognosis of AF progression and recurrence.

6 February 2023 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
RGRifeng Gao
Rifeng Gao
CLChunyu Lv
Chunyu Lv
YQYanan Qu
Yanan Qu
HYHen Yang
Hen Yang
CHChuangze Hao
Chuangze Hao
YTYanhua Tang
Yanhua Tang

6 January 2021 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
JSJiaran Shi
Jiaran Shi
SXShuangbin Xu
Shuangbin Xu
LCLeiyang Chen
Leiyang Chen
BWBifeng Wu
Bifeng Wu
KYKun Yang
Kun Yang
XHXiaosheng Hu
Xiaosheng Hu

1 January 2020 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
DZDongchen Zhou
Dongchen Zhou
KYKun Yang
Kun Yang
JHJingjing Hu
Jingjing Hu
JSJiaran Shi
Jiaran Shi
XHXiaosheng Hu
Xiaosheng Hu
Atrial fibrillation (AF) is an important cause of cardiovascular morbidity and mortality. Current therapies for AF are ineffective, mainly due to incomplete understanding of the pathogenesis of AF. Atrial remodeling contributes to the occurrence and progression of AF, but molecular mechanisms underlying AF remain unclear. Non-coding RNAs, including microRNAs, long non-coding RNAs and circular RNAs, are now considered to play an important role in the pathophysiology of AF. In this review, we summarize recent evidence supporting the role of non-coding RNAs in AF and highlight their diagnostic and prognostic applications as potential biomarkers and therapeutic strategies.

9 October 2025 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
MMMairedan Muhetarijiang
Mairedan Muhetarijiang
PZPengwei Zhu
Pengwei Zhu
HZHan Zhang
Han Zhang
XSXiangjie Sun
Xiangjie Sun
YWYakui Wu
Yakui Wu
TCTing Chen
Ting Chen
Immune checkpoint inhibitors (ICIs), particularly programmed cell death protein 1 (PD-1) blockades, have redefined oncology in the last decade. Previous studies on PD-1 blockades mostly concentrate on their interactions with immune cells. This study aims to investigate how PD-1 blockades affect endothelial cell (EC) heterogeneity in the tumor microenvironment (TME) and to explore potential targets for enhancing the anti-tumor effects of PD-1 blockades. Here, we established a pan-cancer EC atlas from the public database and revealed that PD-1 blockades repress the angiogenic population in ECs and inhibit the CXCL12-CXCR4 signaling derived from ECs. Using a murine tumor model built with Lewis Lung Carcinoma cell line, we further validated our findings that a PD-1 blockade, as well as a CXCR4 antagonist AMD3100, inhibited EC population in tumors and their CXCL12 expression. In addition, the combo therapy of the PD-1 blockade and AMD3100 showed superior anti-tumor effects to monotherapy. Moreover, we predicted MYC to be the potential regulator through which PD-1 blockades affect ECs. Together, our results suggest that PD-1 blockades have an anti-angiogenic effect besides boosting T cell immunity, and the CXCL12/CXCR4 pathway is a potential target for enhancing the effectiveness of PD-1 blockades.